Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease

Gaurav Bedse, Adele Romano, Silvia Cianci, Angelo M. Lavecchia, Pace Lorenzo, Maurice R. Elphick, Frank M. Laferla, Gianluigi Vendemiale, Caterina Grillo, Fabio Altieri, Tommaso Cassano, Silvana Gaetani

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD). However, the association between CB1 alterations and the development of AD neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 protein levels were analyzed in 3 × Tg-AD mice and compared to wild-type littermates at 2, 6 and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), prelimbic cortex, dorsal hippocampus (DH), basolateral amygdala complex (BLA), and ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by neuropathology in 3 × Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA and protein levels in 3 × Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, DH, and BLA, and lower in VH in 3 × Tg-AD mice compared to wild-type littermates. CB1 immunohistochemistry revealed that CB1 protein expression was unchanged in 3 × Tg-AD at 2 and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was detected in the BLA and DH of 12-month-old 3 × Tg-AD mice, with no sign of alteration in other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.

Original languageEnglish
Pages (from-to)701-712
Number of pages12
JournalJournal of Alzheimer's Disease
Volume40
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Cannabinoid Receptor CB1
Transgenic Mice
Alzheimer Disease
Hippocampus
Endocannabinoids
Prefrontal Cortex
Messenger RNA
Brain
Immunohistochemistry
Pathology
Proteins
Neurodegenerative Diseases
In Situ Hybridization
Alzheimer disease, familial, type 3
Therapeutics
Basolateral Nuclear Complex

Keywords

  • 3 × Tg-AD mice
  • Alzheimer's disease
  • basolateral amygdala complex
  • CB1 mRNA
  • CB1 receptor
  • endocannabinoid system
  • hippocampus
  • prefrontal cortex

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology
  • Medicine(all)

Cite this

Bedse, G., Romano, A., Cianci, S., Lavecchia, A. M., Lorenzo, P., Elphick, M. R., ... Gaetani, S. (2014). Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease. Journal of Alzheimer's Disease, 40(3), 701-712. https://doi.org/10.3233/JAD-131910

Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease. / Bedse, Gaurav; Romano, Adele; Cianci, Silvia; Lavecchia, Angelo M.; Lorenzo, Pace; Elphick, Maurice R.; Laferla, Frank M.; Vendemiale, Gianluigi; Grillo, Caterina; Altieri, Fabio; Cassano, Tommaso; Gaetani, Silvana.

In: Journal of Alzheimer's Disease, Vol. 40, No. 3, 2014, p. 701-712.

Research output: Contribution to journalArticle

Bedse, G, Romano, A, Cianci, S, Lavecchia, AM, Lorenzo, P, Elphick, MR, Laferla, FM, Vendemiale, G, Grillo, C, Altieri, F, Cassano, T & Gaetani, S 2014, 'Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease', Journal of Alzheimer's Disease, vol. 40, no. 3, pp. 701-712. https://doi.org/10.3233/JAD-131910
Bedse, Gaurav ; Romano, Adele ; Cianci, Silvia ; Lavecchia, Angelo M. ; Lorenzo, Pace ; Elphick, Maurice R. ; Laferla, Frank M. ; Vendemiale, Gianluigi ; Grillo, Caterina ; Altieri, Fabio ; Cassano, Tommaso ; Gaetani, Silvana. / Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease. In: Journal of Alzheimer's Disease. 2014 ; Vol. 40, No. 3. pp. 701-712.
@article{2eb803d7591547daa8018d2b3b1a8ad6,
title = "Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease",
abstract = "The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD). However, the association between CB1 alterations and the development of AD neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 protein levels were analyzed in 3 × Tg-AD mice and compared to wild-type littermates at 2, 6 and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), prelimbic cortex, dorsal hippocampus (DH), basolateral amygdala complex (BLA), and ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by neuropathology in 3 × Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA and protein levels in 3 × Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, DH, and BLA, and lower in VH in 3 × Tg-AD mice compared to wild-type littermates. CB1 immunohistochemistry revealed that CB1 protein expression was unchanged in 3 × Tg-AD at 2 and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was detected in the BLA and DH of 12-month-old 3 × Tg-AD mice, with no sign of alteration in other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.",
keywords = "3 × Tg-AD mice, Alzheimer's disease, basolateral amygdala complex, CB1 mRNA, CB1 receptor, endocannabinoid system, hippocampus, prefrontal cortex",
author = "Gaurav Bedse and Adele Romano and Silvia Cianci and Lavecchia, {Angelo M.} and Pace Lorenzo and Elphick, {Maurice R.} and Laferla, {Frank M.} and Gianluigi Vendemiale and Caterina Grillo and Fabio Altieri and Tommaso Cassano and Silvana Gaetani",
year = "2014",
doi = "10.3233/JAD-131910",
language = "English",
volume = "40",
pages = "701--712",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of alzheimer's disease

AU - Bedse, Gaurav

AU - Romano, Adele

AU - Cianci, Silvia

AU - Lavecchia, Angelo M.

AU - Lorenzo, Pace

AU - Elphick, Maurice R.

AU - Laferla, Frank M.

AU - Vendemiale, Gianluigi

AU - Grillo, Caterina

AU - Altieri, Fabio

AU - Cassano, Tommaso

AU - Gaetani, Silvana

PY - 2014

Y1 - 2014

N2 - The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD). However, the association between CB1 alterations and the development of AD neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 protein levels were analyzed in 3 × Tg-AD mice and compared to wild-type littermates at 2, 6 and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), prelimbic cortex, dorsal hippocampus (DH), basolateral amygdala complex (BLA), and ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by neuropathology in 3 × Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA and protein levels in 3 × Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, DH, and BLA, and lower in VH in 3 × Tg-AD mice compared to wild-type littermates. CB1 immunohistochemistry revealed that CB1 protein expression was unchanged in 3 × Tg-AD at 2 and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was detected in the BLA and DH of 12-month-old 3 × Tg-AD mice, with no sign of alteration in other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.

AB - The endocannabinoid system has gained much attention as a new potential pharmacotherapeutic target in various neurodegenerative diseases, including Alzheimer's disease (AD). However, the association between CB1 alterations and the development of AD neuropathology is unclear and often contradictory. In this study, brain CB1 mRNA and CB1 protein levels were analyzed in 3 × Tg-AD mice and compared to wild-type littermates at 2, 6 and 12 months of age, using in-situ hybridization and immunohistochemistry, respectively. Semiquantitative analysis of CB1 expression focused on the prefrontal cortex (PFC), prelimbic cortex, dorsal hippocampus (DH), basolateral amygdala complex (BLA), and ventral hippocampus (VH), all areas with high CB1 densities that are strongly affected by neuropathology in 3 × Tg-AD mice. At 2 months of age, there was no change in CB1 mRNA and protein levels in 3 × Tg-AD mice compared to Non-Tg mice in all brain areas analyzed. However, at 6 and 12 months of age, CB1 mRNA levels were significantly higher in PFC, DH, and BLA, and lower in VH in 3 × Tg-AD mice compared to wild-type littermates. CB1 immunohistochemistry revealed that CB1 protein expression was unchanged in 3 × Tg-AD at 2 and 6 months of age, while a significant decrease in CB1 receptor immunoreactivity was detected in the BLA and DH of 12-month-old 3 × Tg-AD mice, with no sign of alteration in other brain areas. The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.

KW - 3 × Tg-AD mice

KW - Alzheimer's disease

KW - basolateral amygdala complex

KW - CB1 mRNA

KW - CB1 receptor

KW - endocannabinoid system

KW - hippocampus

KW - prefrontal cortex

UR - http://www.scopus.com/inward/record.url?scp=84901935478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901935478&partnerID=8YFLogxK

U2 - 10.3233/JAD-131910

DO - 10.3233/JAD-131910

M3 - Article

C2 - 24496074

AN - SCOPUS:84901935478

VL - 40

SP - 701

EP - 712

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -